GMDAQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
GMDAQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Gamida Cell's accounts receivables for the quarter that ended in Dec. 2023 was $1.61 Mil.
Accounts receivable can be measured by Days Sales Outstanding. Gamida Cell's Days Sales Outstanding for the quarter that ended in Dec. 2023 was 132.23.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Gamida Cell's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $-0.39.
The historical data trend for Gamida Cell's Accounts Receivable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gamida Cell Annual Data | |||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Accounts Receivable | Get a 7-Day Free Trial | - | - | - | - | 1.61 |
Gamida Cell Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Accounts Receivable | Get a 7-Day Free Trial | - | - | - | 0.68 | 1.61 |
Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
Gamida Cell's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 1.61 | / | 1.111 | * | 91 |
= | 132.23 |
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Gamida Cell's accounts receivable are only considered to be worth 75% of book value:
Gamida Cell's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:
Net-Net Working Capital Per Share | |||||||
= | (Cash And Cash Equivalents | + | 0.75 * Accounts Receivable | + | 0.5 * Total Inventories | - | Total Liabilities |
- | Preferred Stock | - | Minority Interest) | / | Shares Outstanding (EOP) | ||
= | (46.554 | + | 0.75 * 1.61 | + | 0.5 * 1.906 | - | 105.135 |
- | 0 | - | 0) | / | 144.444 | ||
= | -0.39 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
Thank you for viewing the detailed overview of Gamida Cell's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.
Jeremy Blank | director | 6446 DREXEL AVENUE, LOS ANGELES CA 90048 |
Mary Theresa Coelho | officer: Chief Financial Officer | 52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017 |
Ronit Simantov | officer: CMO & Chief Scientific Officer | 1988 CHAPEL STREET, NEW HAVEN CT 06515 |
Abigail L. Jenkins | director, officer: President and CEO | C/O GAMIDA CELL LTD., 116 HUNTINGTON AVENUE, BOSTON MA 02116 |
Stephen T Wills | director | PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
Ivan M. Borrello | director | C/O GAMIDA CELL LTD., 5 NAHUM HEFTSADIE STREET, GIVAAT SHAUL, JERUSALEM L3 91340 |
Anat Cohen-dayag | director | C/O GAMIDA CELL LTD., 5 NAHUM HEFTSADIE STREET, GIVAAT SHAUL, JERUSALEM L3 91340 |
Naama Halevi-davidov | director | C/O KALTURA, INC., 250 PARK AVENUE SOUTH, 10TH FLOOR, NEW YORK NY 10003 |
Joshua F. Patterson | officer: General Counsel | C/O AKCEA THERAPEUTICS, INC., 22 BOSTON WHARF ROAD, 9TH FLOOR, BOSTON MA 02210 |
Bio Medical Investment (1997) Ltd. | other: Affiliate of 10% Owner | 3 AZRIELI CENTER TRIANGLE, TOWER,, 45TH FLOOR, 132 MENACHEM BEGIN ST., TEL AVIV L3 6702301 |
Shai Lankry | officer: Chief Financial Officer | C/O GAMIDA CELL LTD., 5 NAHUM HEFTSADIE STREET, GIVAAT SHAUL, JERUSALEM L3 91340 |
Ai Gamida Holdings Llc | other: Affiliate of 10% Owner | 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019 |
Ofer Gonen | director | 1/3 HIGH-TECH VILLAGE, GIVAT RAM, P.O. BOX 39264, JERUSALEM L3 9139102 |
Clal Biotechnology Industries Ltd. | other: Affiliate of 10% Owner | 3AZRIELI CENTER TRIANGLE TOWER 45 FLOOR, TEL AVIV L3 67023 |
Len Blavatnik | 10 percent owner | C/O ACCESS INDUSTRIES, 730 FIFTH AVENUE, NEW YORK NY 10019 |
From GuruFocus
By GuruFocus Research • 02-07-2024
By GuruFocus Research • 02-07-2024
By GuruFocus Research • 02-07-2024
By GuruFocus Research • 02-07-2024
By GuruFocus Research • 02-07-2024
By GuruFocus Research • 02-07-2024
By GuruFocus Research • 02-07-2024
By GuruFocus Research • 02-07-2024
By GuruFocus Research • 02-07-2024
By GuruFocus Research • 02-07-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.